|
From Collegiate Presswire's RadioWire (https://www.cpwire.com/radio): Radio The U.S. Food and Drug Administration has announced the approval of NASONEX(R)for the treatment of nasal polyps in patients 18 years of age and older. This marks the first and only F-D-A approval of a nasal inhaled steroid for nasal polyps prior to surgery. Nasal polyps are grape-like growths in the nasal cavity that reduce airflow in the nasal passages, leading to congestion. Surgical removal is commonly used as a last resort. Doctor Ronald Amedee of Tulane University Medical Center in New Orleans: The prevalence of nasal polyps increases with age and the condition affects two to four percent of people in the United States. For more information, visit w-w-w-dot-nasonex-dot-com. WRAP UP: Originally approved in 1997, NASONEX(R) remains the first and only once-daily prescription nasal inhaled steroid indicated to help prevent most seasonal nasal allergy symptoms, including nasal congestion, in adults and children 12 years of age and older and the only nasal inhaled steroid approved to treat nasal allergy symptoms, including nasal congestion, in patients as young as 2 years of age. As a result of the new approval, NASONEX(R) also is indicated for the treatment of nasal polyps in patients 18 years of age and older. NASONEX(R) is a nasal inhaled steroid related to cortisol, a hormone produced naturally by the body, and when used as directed, is safe and nonsedating. NASONEX(R) reduces nasal congestion caused by an allergic reaction. NASONEX(R) provides relief from the nasal symptoms of seasonal and perennial allergic rhinitis, including nasal congestion, sneezing and an itchy, runny nose. Side effects were generally mild and included headache, viral infection, sore throat, nosebleeds, and coughing. Visit w-w-w-dot-nasonex-dot-com for full prescribing information and for more information on treating nasal allergies and polyps. CLICK HERE to download a transcript of this story: CLICK HERE to download a multimedia (MP3) file of this story: © Copyright 2004 Collegiate Presswire, Inc. and NBN/CP RadioWire |